United States government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalised with Covid-19 because it doesn't seem to be helping them.
Independent monitors had paused enrollment in the study two weeks ago because of a possible safety issue.
But today, the National Institute of Allergy and Infectious Diseases, which sponsors the study, said a closer look did not verify a safety problem but found a low chance that the drug would prove helpful for hospitalised patients.
It is a setback for one of the most promising treatment approaches for Covid-19.
US President Donald Trump received a similar experimental, two-antibody drug from Regeneron Pharmaceuticals Inc. on an emergency basis when he caught the coronavirus this month.
I seem to be lurching from pillar to post, Oxygen compressors advice
Table tennis consultant and Gp 
Bad chest x-ray and no dx in sight
